The main risk of thrombolytic drugs is that they may cause bleeding, so patients should be monitored for vital signs during the use of thrombolytic drugs and within 24 hours of administration. The use of thrombolytic drugs is a very effective clinical treatment of cerebral infarction, in the Department of Neurology, if the patient within 6 hours of the onset of thrombolysis indications, and exclude contraindications to thrombolysis can be used intravenous thrombolytic drugs for treatment. The time window for effective salvage of the ischemic hemidiaphragm around necrotic brain tissue is usually considered to be within 4.5 hours of onset for rt-PA and within 6 hours of onset for urokinase. Contraindications to intravenous thrombolysis must be noted if the patient has a previous history of intracranial hemorrhage or the presence of intracranial arteriovenous malformations, aneurysms, brain tumors, and a history of severe head trauma. Thrombolytic drugs are not suitable for treatment in the above cases and the benefits and risks to the patient must be carefully weighed.